The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data
Description:
<jats:sec>
<jats:title>Aim/Objectives/Background</jats:title>
<jats:p>Chronic hepatitis C (CHC) virus infection is a leading cause of liver-related morbidity and mortality. In Germany, as in many other countries, there is a lack of comprehensive epidemiological data. Routine data from sickness funds can support the estimation of the true prevalence and incidence of CHC.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>In this article, the results of annual and quarterly analyses of prevalence and incidence for the years 2007–2013 are presented using data of several German sickness funds.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>Overall, the prevalence rate remained relatively stable at 0.2%, which is lower than the general assumption for Germany of 0.3%.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>We found that despite the introduction of the breakthrough designated triple therapies with telaprevir or boceprevir in 2011, there was no increase of prevalence or incidence between 2010 and 2011.</jats:p>
</jats:sec>